Pearson D - Search Results

1

Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.

Huang Y, Sendzik M, Zhang J, Gao Z, Sun Y, Wang L, Gu J, Zhao K, Yu Z, Zhang L, Zhang Q, Blanz J, Chen Z, Dubost V, Fang D, Feng L, Fu X, Kiffe M, Li L, Luo F, Luo X, Mi Y, Mistry P, Pearson D, Piaia A, Scheufler C, Terranova R, Weiss A, Zeng J, Zhang H, Zhang J, Zhao M, Dillon MP, Jeay S, Qi W, Moggs J, Pissot-Soldermann C, Li E, Atadja P, Lingel A, Oyang C. Huang Y, et al. Among authors: pearson d. J Med Chem. 2022 Apr 14;65(7):5317-5333. doi: 10.1021/acs.jmedchem.1c02148. Epub 2022 Mar 30. J Med Chem. 2022. PMID: 35352560

2

Evaluation of relative MS response factors of drug metabolites for semi-quantitative assessment of chemical liabilities in drug discovery.

Blanz J, Williams G, Dayer J, Délémonté T, Gertsch W, Ramstein P, Aichholz R, Trunzer M, Pearson D. Blanz J, et al. Among authors: pearson d. J Mass Spectrom. 2017 Apr;52(4):210-217. doi: 10.1002/jms.3918. J Mass Spectrom. 2017. PMID: 28152561

3

Micropreparative isolation and NMR structure elucidation of metabolites of the drug candidate 1-isopropyl-4-(4-isopropylphenyl)-6-(prop-2-yn-1-yloxy) quinazolin-2(1H)-one from rat bile and urine.

Blanz J, Délémonté T, Pearson D, Luneau A, Ritzau M, Gertsch W, Ramstein P, Dayer J, Desrayaud S, Braun E, Aichholz R. Blanz J, et al. Among authors: pearson d. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 May 1;989:1-10. doi: 10.1016/j.jchromb.2015.02.044. Epub 2015 Mar 10. J Chromatogr B Analyt Technol Biomed Life Sci. 2015. PMID: 25797717

4

Species-dependent hepatic and intestinal metabolism of selective oestrogen receptor degrader LSZ102 by sulphation and glucuronidation.

Pearson D, Jin Y, Romeo A, Birlinger BL, Schiller H, Ji Y, Gunduz M, Baldoni D, Walles M. Pearson D, et al. Xenobiotica. 2022 Jan;52(1):26-37. doi: 10.1080/00498254.2022.2037027. Epub 2022 Feb 10. Xenobiotica. 2022. PMID: 35098863

5

Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results.

Jaeger U, Worel N, McGuirk JP, Riedell PA, Fleury I, Du Y, Han X, Pearson D, Redondo S, Waller EK. Jaeger U, et al. Among authors: pearson d. Blood Adv. 2023 Jun 13;7(11):2283-2286. doi: 10.1182/bloodadvances.2022007779. Blood Adv. 2023. PMID: 36044388 Free PMC article. Clinical Trial.

6

¹⁹F-NMR-based determination of the absorption, metabolism and excretion of the oral phosphatidylinositol-3-kinase (PI3K) delta inhibitor leniolisib (CDZ173) in healthy volunteers.

Pearson D, Garnier M, Luneau A, James AD, Walles M. Pearson D, et al. Xenobiotica. 2019 Aug;49(8):953-960. doi: 10.1080/00498254.2018.1523488. Epub 2018 Nov 29. Xenobiotica. 2019. PMID: 30215545 Clinical Trial.

7

Absorption, Distribution, Metabolism, and Excretion of [¹⁴C]iptacopan in Healthy Male Volunteers and in In Vivo and In Vitro Studies.

James AD, Kulmatycki K, Poller B, Romeo AA, Van Lier JJ, Klein K, Pearson D. James AD, et al. Among authors: pearson d. Drug Metab Dispos. 2023 Jul;51(7):873-883. doi: 10.1124/dmd.123.001290. Epub 2023 Jun 12. Drug Metab Dispos. 2023. PMID: 37308298

8

Absorption, Distribution, Metabolism, and Excretion of the Oral Prostaglandin D2 Receptor 2 Antagonist Fevipiprant (QAW039) in Healthy Volunteers and In Vitro.

Pearson D, Weiss HM, Jin Y, Jaap van Lier J, Erpenbeck VJ, Glaenzel U, End P, Woessner R, Eggimann F, Camenisch G. Pearson D, et al. Drug Metab Dispos. 2017 Jul;45(7):817-825. doi: 10.1124/dmd.117.075358. Epub 2017 Apr 25. Drug Metab Dispos. 2017. PMID: 28442499 Clinical Trial.

9

Identification of cryptolepine metabolites in rat and human hepatocytes and metabolism and pharmacokinetics of cryptolepine in Sprague Dawley rats.

Forkuo AD, Ansah C, Pearson D, Gertsch W, Cirello A, Amaral A, Spear J, Wright CW, Rynn C. Forkuo AD, et al. Among authors: pearson d. BMC Pharmacol Toxicol. 2017 Dec 22;18(1):84. doi: 10.1186/s40360-017-0188-8. BMC Pharmacol Toxicol. 2017. PMID: 29273084 Free PMC article.

10

Evaluation of cAMS for ¹⁴C microtracer ADME studies: opportunities to change the current drug development paradigm.

Lozac'h F, Fahrni S, Maria D, Welte C, Bourquin J, Synal HA, Pearson D, Walles M, Camenisch G. Lozac'h F, et al. Among authors: pearson d. Bioanalysis. 2018 Mar 1;10(5):321-339. doi: 10.4155/bio-2017-0216. Epub 2018 Feb 16. Bioanalysis. 2018. PMID: 29451392 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,336 results

Search Page